{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:20:32Z","timestamp":1774408832913,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"unspecified","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Little is known about the risk of SLE flares associated with hydroxychloroquine (HCQ) reduction or cessation, especially after ophthalmological screening. We analysed the risk of SLE flares after HCQ reduction or discontinuation after detection of early ophthalmological toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study includes all patients with SLE among the 109 included in the prospective PERFOCTAPS Study and treated with HCQ for at least 5 years. Patients were divided into 3 groups: HCQ maintenance, reduction and discontinuation after intensive ophthalmological screening. Flare occurrence (SELENA-SLEDAI Flare Index) was assessed for 2 years after HCQ reduction or discontinuation or after inclusion in the maintenance group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 85 patients (98% women, mean age 40.0 years, and mean durations of SLE and HCQ treatment 14.4\u00b17.7 years and 12.9\u00b17.2 years, respectively). The PERFOCTAPS Study identified ophthalmological abnormalities in 25 patients (29.4%); these led to dose reduction in 20 patients and discontinuation in 5. Flares occurred in 29 patients (34.1%): 17 (28.3%) in the maintenance group, 10 (50%) in the reduction group and 2 (40%) in the discontinuation group. After adjustment for potential confounders, HCQ reduction was independently associated with the risk of flare (adjusted HR 2.26; 95% CI 1.03 to 4.97). The same trend was observed in the discontinuation group, but was no longer statistically significant (adjusted HR 2.13; 95% CI 0.44 to 10.27).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this prospective study, HCQ reduction due to early suspicion of retinal toxicity was associated with a statistically significantly increased risk of disease flare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02719002\">NCT02719002<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001434","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:59Z","timestamp":1741848839000},"page":"e001434","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Study)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02719002","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02719002","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02719002","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-0790","authenticated-orcid":false,"given":"Joana Isabel","family":"Marques Dias","sequence":"first","affiliation":[{"name":"Internal Medicine, Hospital Beatriz Angelo, Loures, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chevalier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Vasseur","sequence":"additional","affiliation":[{"name":"Clinical Investigation Platform, Rothschild Foundation Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Laumonier","sequence":"additional","affiliation":[{"name":"Electrophysiology Department, Rothschild Foundation Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Derrien","sequence":"additional","affiliation":[{"name":"Electrophysiology Department, Rothschild Foundation Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Morel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Le Guern","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne 2, Centre de R\u00e9f\u00e9rence lupus et syndrome des antiphospholipides, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Mauget Fa\u00ffsse","sequence":"additional","affiliation":[{"name":"Clinical Investigation Platform, Rothschild Foundation Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-3824","authenticated-orcid":false,"given":"Yann","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"},{"name":"Center for Epidemiology and Statistics, Universit\u00e9 Paris Cit\u00e9 (CRESS), INSERM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-9021","authenticated-orcid":false,"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre de R\u00e9f\u00e9rence Maladies Auto-Immunes et Syst\u00e9miques Rares d\u2019Ile de France, AP-HP.Centre, Universit\u00e9 Paris Cit\u00e9, Hospital Cochin, Paris, France"},{"name":"Center for Epidemiology and Statistics, Universit\u00e9 Paris Cit\u00e9 (CRESS), INSERM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025091513460259000_12.1.e001434.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025091513460259000_12.1.e001434.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"2025091513460259000_12.1.e001434.3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025091513460259000_12.1.e001434.4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091513460259000_12.1.e001434.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2025091513460259000_12.1.e001434.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303"},{"key":"2025091513460259000_12.1.e001434.7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/art.42645","article-title":"Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort","volume":"75","author":"Nguyen","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025091513460259000_12.1.e001434.8","doi-asserted-by":"crossref","first-page":"1759720X211073001","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025091513460259000_12.1.e001434.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.11.017"},{"key":"2025091513460259000_12.1.e001434.10","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000789","article-title":"Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine","volume":"9","author":"Almeida-Brasil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025091513460259000_12.1.e001434.11","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215573","article-title":"Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al","volume":"79","author":"Costedoat-Chalumeau","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025091513460259000_12.1.e001434.12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41584-022-00868-3","article-title":"Hydroxychloroquine dose: balancing toxicity and SLE flare risk","volume":"19","author":"Lenfant","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025091513460259000_12.1.e001434.13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091513460259000_12.1.e001434.14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025091513460259000_12.1.e001434.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091513460259000_12.1.e001434.16","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"2025091513460259000_12.1.e001434.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221295"},{"key":"2025091513460259000_12.1.e001434.18","doi-asserted-by":"crossref","first-page":"SI114","DOI":"10.1093\/rheumatology\/kead647","article-title":"Impact of serological activity on flare following clinically inactive disease and remission in childhood-onset systemic lupus erythematosus","volume":"63","author":"Kisaoglu","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025091513460259000_12.1.e001434.19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-020-02282-0","article-title":"Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study","volume":"22","author":"Fernandez-Ruiz","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025091513460259000_12.1.e001434.20","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/rheumatology\/keaa485","article-title":"Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus","volume":"60","author":"Jin","year":"2021","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025091513460259000_12.1.e001434.21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000528146","article-title":"\u201cEn Face\u201d Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening","volume":"246","author":"Mauget-Fa\u00ffsse","year":"2023","journal-title":"Ophthalmologica"},{"key":"2025091513460259000_12.1.e001434.22","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025091513460259000_12.1.e001434.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025091513460259000_12.1.e001434.24","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091513460259000_12.1.e001434.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091513460259000_12.1.e001434.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400817"},{"key":"2025091513460259000_12.1.e001434.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.22156"},{"key":"2025091513460259000_12.1.e001434.28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025091513460259000_12.1.e001434.29","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/rheumatology\/keaa157","article-title":"Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis","volume":"59","author":"Lenfant","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025091513460259000_12.1.e001434.30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/art.41588","article-title":"Different Control Populations May Lead to Different Understanding of Hydroxychloroquine Blood Levels as a Risk Factor for Retinopathy: Comment on the Article by Petri et al","volume":"73","author":"Lenfant","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:46:09Z","timestamp":1757969169000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/lupus-2024-001434"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001434","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}